

~~16.~~ The truncated MCP-2 of claim ~~15~~<sup>13</sup>, wherein the truncated MCP-2 has the amino acid sequence of SEQ ID NO: 5.

~~17.~~ ~~15.~~ The truncated MCP-2 of claim ~~15~~<sup>13</sup>, wherein the truncated MCP-2 lacks NH<sub>2</sub>-terminal amino acids corresponding to amino acid residue 1 of naturally-occurring MCP-2 (SEQ ID NO: 2).

~~18.~~ ~~20.~~ The truncated MCP-2 of claim ~~15~~<sup>13</sup>, wherein the truncated MCP-2 lacks NH<sub>2</sub>-terminal amino acids corresponding to amino acid residues 1-2 of naturally-occurring MCP-2 (SEQ ID NO: 2).

~~19.~~ The truncated MCP-2 of claim ~~15~~<sup>13</sup>, wherein the truncated MCP-2 lacks NH<sub>2</sub>-terminal amino acids corresponding to amino acid residues 1-3 of naturally-occurring MCP-2 (SEQ ID NO: 2).

~~20.~~ ~~22.~~ The truncated MCP-2 of claim ~~15~~<sup>13</sup>, wherein the truncated MCP-2 lacks NH<sub>2</sub>-terminal amino acids corresponding to amino acid residues 1-4 of naturally-occurring MCP-2 (SEQ ID NO: 2).

~~21.~~ ~~23.~~ The truncated MCP-2 of any one of claims ~~15~~<sup>13</sup> through ~~22~~<sup>20</sup>, wherein the truncated MCP-2 is in glycosylated form.

~~22.~~ ~~24.~~ A pharmaceutical composition comprising a truncated MCP-2 of any one of claims ~~15~~<sup>13</sup> through ~~22~~<sup>20</sup> and one or more pharmaceutically acceptable carriers and/or excipients.

~~23.~~ ~~25.~~ A pharmaceutical composition comprising a truncated MCP-2 of claim ~~23~~<sup>21</sup> and one or more pharmaceutically acceptable carriers and/or excipients.